111, Inc. (NASDAQ:YI) Short Interest Up 94.1% in March

111, Inc. (NASDAQ:YI) was the recipient of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 6,600 shares, a growth of 94.1% from the February 28th total of 3,400 shares. Approximately 0.1% of the shares of the company are short sold. Based on an average daily trading volume, of 40,600 shares, the days-to-cover ratio is presently 0.2 days.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. lifted its holdings in 111 by 43,619.9% during the 4th quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company’s stock worth $191,000 after buying an additional 305,339 shares in the last quarter. FIL Ltd purchased a new stake in shares of 111 during the fourth quarter worth $450,000. Finally, Napean Trading & Investment Co Singapore PTE Ltd purchased a new stake in shares of 111 during the fourth quarter worth $245,000. Hedge funds and other institutional investors own 21.32% of the company’s stock.

111 Trading Down 7.7 %

Shares of NASDAQ:YI opened at $9.05 on Friday. The company’s 50 day moving average is $7.76 and its 200 day moving average is $7.43. 111 has a twelve month low of $4.15 and a twelve month high of $14.10. The company has a market cap of $77.40 million, a PE ratio of -2.26 and a beta of 0.46.

111 (NASDAQ:YI) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.04) earnings per share (EPS) for the quarter. The company had revenue of $527.14 million during the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of 111 in a report on Saturday, March 22nd.

About 111

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.